Peter M Izmirly1, Amit Saxena1, Sara K Sahl1, Ummara Shah2, Deborah M Friedman3, Mimi Y Kim4, Jill P Buyon1. 1. Division of Rheumatology, Department of Medicine, New York University School of Medicine, New York, New York, USA. 2. Division of Rheumatology, Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York, New York, USA. 3. Division of Pediatric Cardiology, Department of Pediatrics, New York Medical College, Valhalla, New York, USA. 4. Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York, USA.
Abstract
OBJECTIVES: Extension of disease beyond the atrioventricular (AV) node is associated with increased mortality in cardiac neonatal lupus (NL). Treatment of isolated heart block with fluorinated steroids to prevent disease progression has been considered but published data are limited and discordant regarding efficacy. This study evaluated whether fluorinated steroids given to manage isolated advanced block prevented development of disease beyond the AV node and conferred a survival benefit. METHODS: In this retrospective study of cases enrolled in the Research Registry for NL, inclusion was restricted to anti-SSA/Ro-exposed cases presenting with isolated advanced heart block in utero who either received fluorinated steroids within 1 week of detection (N=71) or no treatment (N=85). Outcomes evaluated were: development of endocardial fibroelastosis, dilated cardiomyopathy and/or hydrops fetalis; mortality and pacemaker implantation. RESULTS: In Cox proportional hazards regression analyses, fluorinated steroids did not significantly prevent development of disease beyond the AV node (adjusted HR=0.90; 95% CI 0.43 to 1.85; p=0.77), reduce mortality (HR=1.63; 95% CI 0.43 to 6.14; p=0.47) or forestall/prevent pacemaker implantation (HR=0.87; 95% CI 0.57 to 1.33; p=0.53). No risk factors for development of disease beyond the AV node were identified. CONCLUSIONS: These data do not provide evidence to support the use of fluorinated steroids to prevent disease progression or death in cases presenting with isolated heart block. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
OBJECTIVES: Extension of disease beyond the atrioventricular (AV) node is associated with increased mortality in cardiac neonatal lupus (NL). Treatment of isolated heart block with fluorinated steroids to prevent disease progression has been considered but published data are limited and discordant regarding efficacy. This study evaluated whether fluorinated steroids given to manage isolated advanced block prevented development of disease beyond the AV node and conferred a survival benefit. METHODS: In this retrospective study of cases enrolled in the Research Registry for NL, inclusion was restricted to anti-SSA/Ro-exposed cases presenting with isolated advanced heart block in utero who either received fluorinated steroids within 1 week of detection (N=71) or no treatment (N=85). Outcomes evaluated were: development of endocardial fibroelastosis, dilated cardiomyopathy and/or hydrops fetalis; mortality and pacemaker implantation. RESULTS: In Cox proportional hazards regression analyses, fluorinated steroids did not significantly prevent development of disease beyond the AV node (adjusted HR=0.90; 95% CI 0.43 to 1.85; p=0.77), reduce mortality (HR=1.63; 95% CI 0.43 to 6.14; p=0.47) or forestall/prevent pacemaker implantation (HR=0.87; 95% CI 0.57 to 1.33; p=0.53). No risk factors for development of disease beyond the AV node were identified. CONCLUSIONS: These data do not provide evidence to support the use of fluorinated steroids to prevent disease progression or death in cases presenting with isolated heart block. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
Entities:
Keywords:
Autoantibodies; Cardiovascular Disease; Corticosteroids; Outcomes research
Authors: Carolina Llanos; Deborah M Friedman; Amit Saxena; Peter M Izmirly; Chung-E Tseng; Renata Dische; Rosanna G Abellar; Marc Halushka; Robert M Clancy; Jill P Buyon Journal: Rheumatology (Oxford) Date: 2012-02-03 Impact factor: 7.580
Authors: Håkan Eliasson; Sven-Erik Sonesson; Gurleen Sharland; Fredrik Granath; John M Simpson; Julene S Carvalho; Hana Jicinska; Viktor Tomek; Joanna Dangel; Paulo Zielinsky; Maria Respondek-Liberska; Matthias W Freund; Mats Mellander; Joaquim Bartrons; Helena M Gardiner Journal: Circulation Date: 2011-10-10 Impact factor: 29.690
Authors: Pilar Brito-Zerón; Peter M Izmirly; Manuel Ramos-Casals; Jill P Buyon; Munther A Khamashta Journal: Nat Rev Rheumatol Date: 2015-03-24 Impact factor: 20.543
Authors: N Costedoat-Chalumeau; Z Amoura; D Le Thi Hong; B Wechsler; D Vauthier; P Ghillani; T Papo; O Fain; L Musset; J-C Piette Journal: Ann Rheum Dis Date: 2003-10 Impact factor: 19.103
Authors: J W Mason; J B O'Connell; A Herskowitz; N R Rose; B M McManus; M E Billingham; T E Moon Journal: N Engl J Med Date: 1995-08-03 Impact factor: 91.245
Authors: Lilian M Lopes; Gláucia Maria Penha Tavares; Ana Paula Damiano; Marco Antônio Borges Lopes; Vera Demarchi Aiello; Regina Schultz; Marcelo Zugaib Journal: Circulation Date: 2008-09-02 Impact factor: 29.690
Authors: Megan E B Clowse; Amanda M Eudy; Elizabeth Kiernan; Matthew R Williams; Bonnie Bermas; Eliza Chakravarty; Lisa R Sammaritano; Christina D Chambers; Jill Buyon Journal: Rheumatology (Oxford) Date: 2018-07-01 Impact factor: 7.580
Authors: Robert M Clancy; Androo J Markham; Tanisha Jackson; Sara E Rasmussen; Miroslav Blumenberg; Jill P Buyon Journal: Am J Physiol Heart Circ Physiol Date: 2017-06-16 Impact factor: 4.733
Authors: Federica Vanoni; Sebastiano A G Lava; Emilio F Fossali; Riccardo Cavalli; Giacomo D Simonetti; Mario G Bianchetti; Marie-Ange Bozzini; Carlo Agostoni; Gregorio P Milani Journal: Clin Rev Allergy Immunol Date: 2017-12 Impact factor: 8.667